Replimune Group (NASDAQ:REPL) Stock Price Down 5.6% - What's Next?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price traded down 5.6% on Friday . The stock traded as low as $10.99 and last traded at $10.95. 384,744 shares traded hands during trading, a decline of 45% from the average session volume of 694,876 shares. The stock had previously closed at $11.60.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright lifted their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $19.43.

Replimune Group Trading Up 2.1 %

The company has a market cap of $851.02 million, a P/E ratio of -3.60 and a beta of 1.30. The business has a fifty day simple moving average of $12.66 and a 200 day simple moving average of $12.16. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Remove Ads

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of REPL. Wellington Management Group LLP lifted its holdings in Replimune Group by 352.5% in the fourth quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock worth $13,282,000 after acquiring an additional 854,346 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Replimune Group by 25.9% during the 4th quarter. California State Teachers Retirement System now owns 42,725 shares of the company's stock worth $517,000 after purchasing an additional 8,793 shares during the period. Woodline Partners LP raised its position in shares of Replimune Group by 156.6% during the 4th quarter. Woodline Partners LP now owns 854,309 shares of the company's stock worth $10,346,000 after purchasing an additional 521,366 shares during the period. Velan Capital Investment Management LP bought a new stake in shares of Replimune Group in the 4th quarter worth approximately $2,196,000. Finally, Soleus Capital Management L.P. acquired a new position in Replimune Group during the 4th quarter valued at approximately $3,179,000. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.